Court hands No­var­tis win in Gilenya patent fight; US states seek $26B+ in opi­oid cri­sis law­suit

No­var­tis has picked up a win in a long-run­ning patent fight against gener­ic ver­sions of its mul­ti­ple scle­ro­sis drug.

The com­pa­ny an­nounced Mon­day af­ter­noon that the va­lid­i­ty of its Gilenya, or fin­golimod, dos­ing reg­i­men has been up­held by the US Dis­trict Court of Delaware. As a re­sult, a com­pet­ing gener­ic fin­golimod be­ing pro­duced by HEC Pharm in­fringes on No­var­tis’ patent. The rul­ing can still be ap­pealed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER